{"id":4403,"date":"2026-02-17T13:05:32","date_gmt":"2026-02-17T12:05:32","guid":{"rendered":"https:\/\/mikrobiomik.net\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01-as-the-first-gut-microbiota-based-biological-therapy-authorised-in-spain\/"},"modified":"2026-02-17T13:07:41","modified_gmt":"2026-02-17T12:07:41","slug":"mikrobiomik-has-obtained-approval-for-eutegra-mbk-01","status":"publish","type":"post","link":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/","title":{"rendered":"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain"},"content":{"rendered":"[vc_row type=&#8221;in_container&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;dark&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; row_position_desktop=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; overlay_strength=&#8221;0.3&#8243; gradient_direction=&#8221;left_to_right&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221;][vc_column column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; flex_gap_desktop=&#8221;10px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221; background_color_opacity=&#8221;1&#8243; background_hover_color_opacity=&#8221;1&#8243; column_backdrop_filter=&#8221;none&#8221; column_shadow=&#8221;none&#8221; column_border_radius=&#8221;none&#8221; column_link_target=&#8221;_self&#8221; column_position=&#8221;default&#8221; gradient_direction=&#8221;left_to_right&#8221; overlay_strength=&#8221;0.3&#8243; width=&#8221;1\/1&#8243; tablet_width_inherit=&#8221;default&#8221; animation_type=&#8221;default&#8221; bg_image_animation=&#8221;none&#8221; border_type=&#8221;simple&#8221; column_border_width=&#8221;none&#8221; column_border_style=&#8221;solid&#8221;][vc_column_text css=&#8221;&#8221; text_direction=&#8221;default&#8221;]\n<h2>Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain under the new European SoHO Regulation.<\/h2>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-4398 size-full\" src=\"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega.png\" alt=\"Approval for EUTEGRA \" width=\"851\" height=\"315\" srcset=\"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega.png 851w, https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega-300x111.png 300w, https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega-768x284.png 768w\" sizes=\"auto, (max-width: 851px) 100vw, 851px\" \/><\/p>\n<p>&nbsp;<\/p>\n<p>This is a pioneering advance:<\/p>\n<ul>\n<li>First innovative therapy in oral capsules based on microbiota for Clostridioides difficile infection (CDI).<\/li>\n<li>First authorization in Europe under the new SoHO regulatory framework.<span style=\"color: #ff6600;\">[1]<\/span><\/li>\n<li>The treatment has been administered to more than 200 patients in 35 Spanish hospitals in the compassionate use program and during the phase III clinical trial.<\/li>\n<\/ul>\n<p><strong>EUTEGRA (MBK-01)<\/strong> reduces recurrences by more than 50% compared to standard antibiotic treatment and can lead to significant savings for the healthcare system in a disease that represents one of the main hospital infections in developed countries.<\/p>\n<p>This achievement not only opens a new therapeutic category in microbiota, but also positions Spain as a <strong>benchmark in the implementation of the SoHO Regulation and in the development of innovative biological therapies.<\/strong><\/p>\n<p>This is a step forward for biomedical innovation, the sustainability of the healthcare system and, above all, for patients who needed new therapeutic alternatives.<\/p>\n<p><a href=\"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutregra-en.pdf\" target=\"_blank\" rel=\"noopener\"><strong>Download the press release (PDF) here.<\/strong><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #ff6600;\">[1]<\/span> Regulation (EU) 2024\/1938 SoHO (Substances of Human Origin)[\/vc_column_text][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row type=&#8221;in_container&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;dark&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; row_position_desktop=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; overlay_strength=&#8221;0.3&#8243; gradient_direction=&#8221;left_to_right&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221;][vc_column column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; flex_gap_desktop=&#8221;10px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221;&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4398,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[81,96,70],"tags":[],"class_list":{"0":"post-4403","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-biological-medicine","8":"category-mbk-01","9":"category-news-en"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain - Mikrobiomik<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain - Mikrobiomik\" \/>\n<meta property=\"og:description\" content=\"[vc_row type=&#8221;in_container&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;dark&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; row_position_desktop=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; overlay_strength=&#8221;0.3&#8243; gradient_direction=&#8221;left_to_right&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221;][vc_column column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; flex_gap_desktop=&#8221;10px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221;...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/\" \/>\n<meta property=\"og:site_name\" content=\"Mikrobiomik\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-17T12:05:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-17T12:07:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega.png\" \/>\n\t<meta property=\"og:image:width\" content=\"851\" \/>\n\t<meta property=\"og:image:height\" content=\"315\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"elen9miKK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"elen9miKK\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/\"},\"author\":{\"name\":\"elen9miKK\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#\\\/schema\\\/person\\\/5aab4530d1d35b96f96e85aa3d4ca9c9\"},\"headline\":\"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain\",\"datePublished\":\"2026-02-17T12:05:32+00:00\",\"dateModified\":\"2026-02-17T12:07:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/\"},\"wordCount\":384,\"publisher\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mikrobiomik.net\\\/wp-content\\\/uploads\\\/np-eutrega.png\",\"articleSection\":[\"Biological medicine\",\"MBK-01\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/\",\"url\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/\",\"name\":\"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain - Mikrobiomik\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mikrobiomik.net\\\/wp-content\\\/uploads\\\/np-eutrega.png\",\"datePublished\":\"2026-02-17T12:05:32+00:00\",\"dateModified\":\"2026-02-17T12:07:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mikrobiomik.net\\\/wp-content\\\/uploads\\\/np-eutrega.png\",\"contentUrl\":\"https:\\\/\\\/mikrobiomik.net\\\/wp-content\\\/uploads\\\/np-eutrega.png\",\"width\":851,\"height\":315,\"caption\":\"Aprobaci\u00f3n de EUTEGRA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/en\\\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/mikrobiomik.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#website\",\"url\":\"https:\\\/\\\/mikrobiomik.net\\\/\",\"name\":\"Mikrobiomik\",\"description\":\"Terapias biol\u00f3gicas\",\"publisher\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mikrobiomik.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#organization\",\"name\":\"Mikrobiomik\",\"url\":\"https:\\\/\\\/mikrobiomik.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/mikrobiomik.net\\\/wp-content\\\/uploads\\\/mikrobiomik-600.png\",\"contentUrl\":\"https:\\\/\\\/mikrobiomik.net\\\/wp-content\\\/uploads\\\/mikrobiomik-600.png\",\"width\":600,\"height\":171,\"caption\":\"Mikrobiomik\"},\"image\":{\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/mikrobiomik\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mikrobiomik.net\\\/#\\\/schema\\\/person\\\/5aab4530d1d35b96f96e85aa3d4ca9c9\",\"name\":\"elen9miKK\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain - Mikrobiomik","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/","og_locale":"en_US","og_type":"article","og_title":"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain - Mikrobiomik","og_description":"[vc_row type=&#8221;in_container&#8221; full_screen_row_position=&#8221;middle&#8221; column_margin=&#8221;default&#8221; column_direction=&#8221;default&#8221; column_direction_tablet=&#8221;default&#8221; column_direction_phone=&#8221;default&#8221; scene_position=&#8221;center&#8221; text_color=&#8221;dark&#8221; text_align=&#8221;left&#8221; row_border_radius=&#8221;none&#8221; row_border_radius_applies=&#8221;bg&#8221; row_position_desktop=&#8221;default&#8221; row_position_tablet=&#8221;inherit&#8221; row_position_phone=&#8221;inherit&#8221; overflow=&#8221;visible&#8221; overlay_strength=&#8221;0.3&#8243; gradient_direction=&#8221;left_to_right&#8221; shape_divider_position=&#8221;bottom&#8221; bg_image_animation=&#8221;none&#8221;][vc_column column_padding=&#8221;no-extra-padding&#8221; column_padding_tablet=&#8221;inherit&#8221; column_padding_phone=&#8221;inherit&#8221; column_padding_position=&#8221;all&#8221; flex_gap_desktop=&#8221;10px&#8221; column_element_direction_desktop=&#8221;default&#8221; column_element_spacing=&#8221;default&#8221; desktop_text_alignment=&#8221;default&#8221; tablet_text_alignment=&#8221;default&#8221; phone_text_alignment=&#8221;default&#8221;...","og_url":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/","og_site_name":"Mikrobiomik","article_published_time":"2026-02-17T12:05:32+00:00","article_modified_time":"2026-02-17T12:07:41+00:00","og_image":[{"width":851,"height":315,"url":"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega.png","type":"image\/png"}],"author":"elen9miKK","twitter_card":"summary_large_image","twitter_misc":{"Written by":"elen9miKK","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/#article","isPartOf":{"@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/"},"author":{"name":"elen9miKK","@id":"https:\/\/mikrobiomik.net\/#\/schema\/person\/5aab4530d1d35b96f96e85aa3d4ca9c9"},"headline":"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain","datePublished":"2026-02-17T12:05:32+00:00","dateModified":"2026-02-17T12:07:41+00:00","mainEntityOfPage":{"@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/"},"wordCount":384,"publisher":{"@id":"https:\/\/mikrobiomik.net\/#organization"},"image":{"@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/#primaryimage"},"thumbnailUrl":"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega.png","articleSection":["Biological medicine","MBK-01","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/","url":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/","name":"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain - Mikrobiomik","isPartOf":{"@id":"https:\/\/mikrobiomik.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/#primaryimage"},"image":{"@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/#primaryimage"},"thumbnailUrl":"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega.png","datePublished":"2026-02-17T12:05:32+00:00","dateModified":"2026-02-17T12:07:41+00:00","breadcrumb":{"@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/#primaryimage","url":"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega.png","contentUrl":"https:\/\/mikrobiomik.net\/wp-content\/uploads\/np-eutrega.png","width":851,"height":315,"caption":"Aprobaci\u00f3n de EUTEGRA"},{"@type":"BreadcrumbList","@id":"https:\/\/mikrobiomik.net\/en\/mikrobiomik-has-obtained-approval-for-eutegra-mbk-01\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/mikrobiomik.net\/"},{"@type":"ListItem","position":2,"name":"Mikrobiomik has obtained approval for EUTEGRA (MBK-01) as the first gut microbiota-based biological therapy authorised in Spain"}]},{"@type":"WebSite","@id":"https:\/\/mikrobiomik.net\/#website","url":"https:\/\/mikrobiomik.net\/","name":"Mikrobiomik","description":"Terapias biol\u00f3gicas","publisher":{"@id":"https:\/\/mikrobiomik.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mikrobiomik.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mikrobiomik.net\/#organization","name":"Mikrobiomik","url":"https:\/\/mikrobiomik.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mikrobiomik.net\/#\/schema\/logo\/image\/","url":"https:\/\/mikrobiomik.net\/wp-content\/uploads\/mikrobiomik-600.png","contentUrl":"https:\/\/mikrobiomik.net\/wp-content\/uploads\/mikrobiomik-600.png","width":600,"height":171,"caption":"Mikrobiomik"},"image":{"@id":"https:\/\/mikrobiomik.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/mikrobiomik"]},{"@type":"Person","@id":"https:\/\/mikrobiomik.net\/#\/schema\/person\/5aab4530d1d35b96f96e85aa3d4ca9c9","name":"elen9miKK"}]}},"_links":{"self":[{"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/posts\/4403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/comments?post=4403"}],"version-history":[{"count":2,"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/posts\/4403\/revisions"}],"predecessor-version":[{"id":4405,"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/posts\/4403\/revisions\/4405"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/media\/4398"}],"wp:attachment":[{"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/media?parent=4403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/categories?post=4403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mikrobiomik.net\/en\/wp-json\/wp\/v2\/tags?post=4403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}